Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 248

1.

Regulation of target genes of PAX3-FOXO1 in alveolar rhabdomyosarcoma.

Ahn EH.

Anticancer Res. 2013 May;33(5):2029-35.

PMID:
23645752
2.

Identification of target genes of PAX3-FOXO1 in alveolar rhabdomyosarcoma.

Ahn EH, Mercado GE, Laé M, Ladanyi M.

Oncol Rep. 2013 Aug;30(2):968-78. doi: 10.3892/or.2013.2513. Epub 2013 Jun 3.

3.

Secreted Frizzled-Related Protein 3 (SFRP3) Is Required for Tumorigenesis of PAX3-FOXO1-Positive Alveolar Rhabdomyosarcoma.

Kephart JJ, Tiller RG, Crose LE, Slemmons KK, Chen PH, Hinson AR, Bentley RC, Chi JT, Linardic CM.

Clin Cancer Res. 2015 Nov 1;21(21):4868-80. doi: 10.1158/1078-0432.CCR-14-1797. Epub 2015 Jun 12.

4.

A chimeric RNA characteristic of rhabdomyosarcoma in normal myogenesis process.

Yuan H, Qin F, Movassagh M, Park H, Golden W, Xie Z, Zhang P, Sklar J, Li H.

Cancer Discov. 2013 Dec;3(12):1394-403. doi: 10.1158/2159-8290.CD-13-0186. Epub 2013 Oct 2.

5.

Alveolar rhabdomyosarcoma-associated proteins PAX3/FOXO1A and PAX7/FOXO1A suppress the transcriptional activity of MyoD-target genes in muscle stem cells.

Calhabeu F, Hayashi S, Morgan JE, Relaix F, Zammit PS.

Oncogene. 2013 Jan 31;32(5):651-62. doi: 10.1038/onc.2012.73. Epub 2012 Jun 18.

PMID:
22710712
6.

The Polycomb group (PcG) protein EZH2 supports the survival of PAX3-FOXO1 alveolar rhabdomyosarcoma by repressing FBXO32 (Atrogin1/MAFbx).

Ciarapica R, De Salvo M, Carcarino E, Bracaglia G, Adesso L, Leoncini PP, Dall'Agnese A, Walters ZS, Verginelli F, De Sio L, Boldrini R, Inserra A, Bisogno G, Rosolen A, Alaggio R, Ferrari A, Collini P, Locatelli M, Stifani S, Screpanti I, Rutella S, Yu Q, Marquez VE, Shipley J, Valente S, Mai A, Miele L, Puri PL, Locatelli F, Palacios D, Rota R.

Oncogene. 2014 Aug 7;33(32):4173-84. doi: 10.1038/onc.2013.471. Epub 2013 Nov 11.

PMID:
24213577
7.

Structural and functional studies of FKHR-PAX3, a reciprocal fusion gene of the t(2;13) chromosomal translocation in alveolar rhabdomyosarcoma.

Hu Q, Yuan Y, Wang C.

PLoS One. 2013 Jun 14;8(6):e68065. doi: 10.1371/journal.pone.0068065. Print 2013.

8.

Identification of PAX3-FKHR-regulated genes differentially expressed between alveolar and embryonal rhabdomyosarcoma: focus on MYCN as a biologically relevant target.

Mercado GE, Xia SJ, Zhang C, Ahn EH, Gustafson DM, Laé M, Ladanyi M, Barr FG.

Genes Chromosomes Cancer. 2008 Jun;47(6):510-20. doi: 10.1002/gcc.20554.

PMID:
18335505
9.

Alveolar rhabdomyosarcoma-associated PAX3-FOXO1 promotes tumorigenesis via Hippo pathway suppression.

Crose LE, Galindo KA, Kephart JG, Chen C, Fitamant J, Bardeesy N, Bentley RC, Galindo RL, Chi JT, Linardic CM.

J Clin Invest. 2014 Jan;124(1):285-96. doi: 10.1172/JCI67087. Epub 2013 Dec 16.

10.

P/CAF mediates PAX3-FOXO1-dependent oncogenesis in alveolar rhabdomyosarcoma.

Bharathy N, Suriyamurthy S, Rao VK, Ow JR, Lim HJ, Chakraborty P, Vasudevan M, Dhamne CA, Chang KT, Min VL, Kundu TK, Taneja R.

J Pathol. 2016 Nov;240(3):269-281. doi: 10.1002/path.4773. Epub 2016 Sep 27.

PMID:
27453350
11.

Guilt by association: PAX3-FOXO1 regulates gene expression through selective destabilization of the EGR1 transcription factor.

Roeb W, Boyer A, Cavenee WK, Arden KC.

Cell Cycle. 2008 Apr 1;7(7):837-41. Epub 2008 Jan 22. Erratum in: Cell Cycle. 2008 Oct;7(19):3106.

PMID:
18414034
12.

Small molecule inhibition of PAX3-FOXO1 through AKT activation suppresses malignant phenotypes of alveolar rhabdomyosarcoma.

Jothi M, Mal M, Keller C, Mal AK.

Mol Cancer Ther. 2013 Dec;12(12):2663-74. doi: 10.1158/1535-7163.MCT-13-0277. Epub 2013 Oct 9.

13.

Validation of met as a therapeutic target in alveolar and embryonal rhabdomyosarcoma.

Taulli R, Scuoppo C, Bersani F, Accornero P, Forni PE, Miretti S, Grinza A, Allegra P, Schmitt-Ney M, Crepaldi T, Ponzetto C.

Cancer Res. 2006 May 1;66(9):4742-9.

14.

Analysis of genetic events that modulate the oncogenic and growth suppressive activities of the PAX3-FKHR fusion oncoprotein.

Xia SJ, Rajput P, Strzelecki DM, Barr FG.

Lab Invest. 2007 Apr;87(4):318-25. Epub 2007 Feb 12.

15.

PAX3-FOXO1 induces cannabinoid receptor 1 to enhance cell invasion and metastasis.

Marshall AD, Lagutina I, Grosveld GC.

Cancer Res. 2011 Dec 15;71(24):7471-80. doi: 10.1158/0008-5472.CAN-11-0924. Epub 2011 Oct 28.

16.

The cooperative transforming effects of PAX3-FKHR and IGF-II on mouse myoblasts.

Wang W, Slevin M, Kumar S, Kumar P.

Int J Oncol. 2005 Oct;27(4):1087-96.

PMID:
16142327
17.

A call to ARMS: targeting the PAX3-FOXO1 gene in alveolar rhabdomyosarcoma.

Olanich ME, Barr FG.

Expert Opin Ther Targets. 2013 May;17(5):607-23. doi: 10.1517/14728222.2013.772136. Epub 2013 Feb 25. Review.

PMID:
23432728
18.

Cell-based small-molecule compound screen identifies fenretinide as potential therapeutic for translocation-positive rhabdomyosarcoma.

Herrero Martín D, Boro A, Schäfer BW.

PLoS One. 2013;8(1):e55072. doi: 10.1371/journal.pone.0055072. Epub 2013 Jan 25.

19.

Phosphorylation of serine 205 by the protein kinase CK2 persists on Pax3-FOXO1, but not Pax3, throughout early myogenic differentiation.

Dietz KN, Miller PJ, Hollenbach AD.

Biochemistry. 2009 Dec 15;48(49):11786-95. doi: 10.1021/bi9012947.

Supplemental Content

Support Center